Fintel reports that on March 31, 2025, HC Wainwright & Co. initiated coverage of Virax Biolabs Group (NasdaqCM:VRAX) with a ...

H.C. Wainwright raised the firm’s price target on Corcept Therapeutics (CORT) to $150 from $115 and keeps a Buy rating on the shares after the ...

H.C. Wainwright keeps a Buy rating on Tenaya Therapeutics (TNYA) with a $5 price target after the company presented an interim update from the ...

Equities researchers at HC Wainwright raised their FY2025 earnings per share estimates for shares of Integra Resources in a ...

Virax Biolabs' T-cell testing platform targets post-viral syndromes like Long COVID. HC Wainwright sees a major market opportunity, setting a $3 price target.

Equities researchers at HC Wainwright issued their Q4 2025 earnings estimates for Nkarta in a note issued to investors on ...

H.C. Wainwright keeps a Buy rating on Milestone Pharmaceuticals (MIST) after the company announced receipt of a complete response letter from the ...

H.C. Wainwright analyst Joseph Pantginis raised the firm’s price target on Aptose Biosciences (APTO) to $6 from $2 and keeps ...

Fintel reports that on March 27, 2025, HC Wainwright & Co. initiated coverage of RenovoRx (NasdaqCM:RNXT) with a Buy recommendation. As of March 19, 2025, the average one-year price target for ...

H.C. Wainwright says Novo Nordisk’s (NVO) REDEFINE-2 results reinforce Viking Therapeutics’ (VKTX) VK2735’s potential in obesity and beyond. Assuming full adherence, Novo’s CagriSema ...

On Thursday, 27 March 2025, Nektar Therapeutics (NASDAQ: NKTR) participated in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference. The company provided a strategic ...

On Friday, H.C. Wainwright reaffirmed its Buy rating and a price target of $11.50 on Innate Pharma (EPA:IPH) S.A. (NASDAQ:IPHA), representing significant upside from the current price of $1.97.